These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27344809)

  • 1. [Sequential therapy for castration-resistant prostate cancer].
    Nozawa M; Uemura H
    Nihon Rinsho; 2016 May; 74 Suppl 3():644-8. PubMed ID: 27344809
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 3. AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?
    Tsaur I; Borgmann H; Surcel CI; Ost P; Ploussard G
    World J Urol; 2018 Jan; 36(1):149-151. PubMed ID: 29086020
    [No Abstract]   [Full Text] [Related]  

  • 4. Galeterone activity in castration-resistant prostate cancer.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
    Martinez-Ariza G; Hulme C
    Pharm Pat Anal; 2015; 4(5):387-402. PubMed ID: 26389532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
    Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
    Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
    [No Abstract]   [Full Text] [Related]  

  • 7. The biology of castration-resistant prostate cancer.
    Lian F; Sharma NV; Moran JD; Moreno CS
    Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
    [No Abstract]   [Full Text] [Related]  

  • 8. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alternative antiandrogen therapy for castration-resistant prostate cancer].
    Suzuki H; Utsumi T; Endo T; Kamijima S; Kamiya N
    Nihon Rinsho; 2016 May; 74 Suppl 3():589-94. PubMed ID: 27344799
    [No Abstract]   [Full Text] [Related]  

  • 10. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
    Hakariya T; Sakai H
    Nihon Rinsho; 2016 Jan; 74(1):137-42. PubMed ID: 26793894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator.
    Mistry HB; Fabre MA; Young J; Clack G; Dickinson PA
    CPT Pharmacometrics Syst Pharmacol; 2016 May; 5(5):258-63. PubMed ID: 27299938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
    Hu YH; Guo JC; Zhang M
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darolutamide for treatment of castration-resistant prostate cancer.
    Rhea LP; Mendez-Marti S; Aragon-Ching JB
    Drugs Today (Barc); 2020 Mar; 56(3):185-193. PubMed ID: 32282865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.
    Blas L; Shiota M
    Curr Cancer Drug Targets; 2023; 23(6):428-432. PubMed ID: 36803751
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on systemic therapy for advance prostate cancer.
    Carthon B; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):52-62. PubMed ID: 25637932
    [No Abstract]   [Full Text] [Related]  

  • 19. Apalutamide shows efficacy in prostate cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e149. PubMed ID: 29456088
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies for targeting the androgen receptor axis in prostate cancer.
    Carver BS
    Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.